A Phase 1/2 Dose Escalation and Dose Expansion Study of BA3011 in Patients With Advanced Solid Tumors
Not yet recruiting
Phase of Trial: Phase I/II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs BA 3011 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors BioAtla
- 06 Feb 2018 Status changed from planning to not yet recruiting.
- 25 Jan 2018 New trial record
- 24 Jan 2018 According to a Bioatla media release, the U.S. Food and Drug Administration (FDA) has cleared BioAtla's Investigational New Drug application (IND) for BA3011.